Impax Asset Management Group’s Ligand Pharmaceuticals LGND Stock Holding History

Impax Asset Management Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.1M	Sell	130,000 -22,444	-15%	-$5.29M	0.27%	75
2026 Q1	$30.4M	Sell	152,444 -12,764	-8%	-$2.53M	0.21%	85
2025 Q4	$31.2M	Sell	165,208 -35,000	-17%	-$6.73M	0.2%	89
2025 Q3	$35.5M	Sell	200,208 -60,000	-23%	-$8.92M	0.21%	82
2025 Q2	$29.6M	Sell	260,208 -20,000	-7%	-$2.14M	0.17%	91
2025 Q1	$29.5M	Hold	280,208	–	–	0.18%	93
2024 Q4	$30M	Hold	280,208	–	–	0.14%	105
2024 Q3	$28M	Hold	280,208	–	–	0.11%	113
2024 Q2	$23.6M	Buy	280,208 +25,000	+10%	+$1.99M	0.1%	119
2024 Q1	$18.7M	Buy	255,208 +50,000	+24%	+$3.69M	0.07%	134
2023 Q4	$14.7M	Buy	205,208 +20,888	+11%	+$1.23M	0.06%	139
2023 Q3	$11M	Buy	184,320 +25,000	+16%	+$1.65M	0.05%	156
2023 Q2	$11.5M	Sell	159,320 -35,000	-18%	-$2.63M	0.05%	151
2023 Q1	$14.3M	Sell	194,320 -40,000	-17%	-$2.84M	0.06%	136
2022 Q4	$15.7M	Sell	234,320 -141,295	-38%	-$9.19M	0.07%	128
2022 Q3	$20.2M	Buy	375,615 +80,150	+27%	+$4.71M	0.1%	117
2022 Q2	$16.4M	Buy	295,465 +32,060	+12%	+$1.82M	0.08%	126
2022 Q1	$18.5M	Buy	263,405 +47,289	+22%	+$3.43M	0.08%	127
2021 Q4	$20.8M	Buy	216,116 +56,906	+36%	+$5.26M	0.08%	126
2021 Q3	$13.8M	Buy	159,210 +32,060	+25%	+$2.48M	0.06%	133
2021 Q2	$10.4M	Sell	127,150 -8,161	-6%	-$679K	0.05%	151
2021 Q1	$12.9M	Sell	135,311 -65,973	-33%	-$6.24M	0.07%	123
2020 Q4	$12.5M	Hold	201,284	–	–	0.08%	113
2020 Q3	$12M	Buy	201,284 +14,007	+7%	+$956K	0.1%	110
2020 Q2	$13.1M	Hold	187,277	–	–	0.13%	104
2020 Q1	$8.5M	Buy	187,277 +64,120	+52%	+$3.63M	0.11%	113
2019 Q4	$8.01M	Buy	123,157 +7,255	+6%	+$485K	0.09%	134
2019 Q3	$7.2M	Hold	115,902	–	–	0.09%	141
2019 Q2	$8.25M	Sell	115,902 -13,875	-11%	-$1.02M	0.11%	120
2019 Q1	$10.2M	Hold	129,777	–	–	0.14%	115
2018 Q4	$11M	Buy	129,777 +80,150	+162%	+$8.54M	0.18%	101
2018 Q3	$8.5M	Buy	+49,627	New	+$7.48M	0.12%	137

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Impax Asset Management Group's LGND Position: Q2 2026 in Review

Impax Asset Management Group reduced its Ligand Pharmaceuticals (LGND) stake by 15% in Q2 2026, selling an estimated $5.29M and leaving 130,000 shares worth $41.1M. The position accounts for 0.27% of the portfolio, ranked #75.

Impax Asset Management Group first reported a position in LGND in Q3 2018 and has held it in 32 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Impax Asset Management Group held 130,000 shares of Ligand Pharmaceuticals worth $41.1M as of Q2 2026.
Impax Asset Management Group sold 22,444 Ligand Pharmaceuticals shares in Q2 2026, an estimated $5.29M.
Ligand Pharmaceuticals made up 0.27% of Impax Asset Management Group's portfolio in Q2 2026, its #75 holding.
Impax Asset Management Group first reported a position in Ligand Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.